|
Through the OFS, the company's promoter Adimans Technologies LLP proposes to sell over 68.98 lakh shares, constituting 4.4% paid-up share capital of the company, with an option to sell an additional 4.4% stake or 68.98 lakh equity shares (oversubscription option).
Adimans Technologies LLP held 63.2% stake or 9,90,91,898 shares of Dishman Carbogen as of 30 September 2020.
The floor price for the OFS was set at Rs 145.70 per shares, at a 15.52% discount to Dishman Carbogen's closing price of Rs 154.90 on Thursday, 17 December 2020.
The OFS opened on Friday (18 December 2020) for non-retail investors, while both retail as well as non-retail investors will be able to subscribe on Monday (21 December 2020). A total of 15% of the offer size has been reserved for retail investors.
As on 12:15 IST, the OFS received subscription for 19,670 shares or 0.34% against the base non-retail offer size of 58,63,688 shares.
Dishman Carbogen Amcis offers a portfolio of drug development and commercialization services to the pharmaceutical and bio-pharmaceutical industries at all stages of drug development.
On a consolidated basis, the company's net profit declined 82.1% to Rs 7.38 crore on a 2.1% fall in net sales to Rs 440.42 crore in Q2 September 2020 over Q2 September 2019.
|